• Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer Cells With The Vision to Bring “Off-The-Shelf” NK Cell-Based Cancer Treatments Rapidly

    12 days ago - By San Diego Biotechnology

    SAN DIEGO and STOCKHOLM, Sweden, June 04, 2021 - Sorrento Therapeutics, Inc. ?today announced that the Company has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at the Department of Medicine, Huddinge, Karolinska?Institutet? in?Stockholm, Sweden, aimed at producing novel?cell-based therapeutics using natural killer...
    Read more ...

     

  • Sorrento Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166, a Novel HER2 ADC for Advanced HER2 Positive Breast Cancers

    12 days ago - By San Diego Biotechnology

    SAN DIEGO, June 04, 2021 - Sorrento Therapeutics, Inc. today announced that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. , a license and development partner, will present posters at this year's American Society of Clinical Oncology meeting to be held June 5-6, 2021, releasing Phase...
    Read more ...